What does 75 lakh in seized violations really represent

The Maharashtra Food and Drug Administration's seizure of products worth ₹75 lakh may appear to signal strong enforcement. But the recent cases raise a larger question: how much unsafe, adulterated or substandard food and medicine reaches consumers before regulators detect it?

Across three very different frontiers, Maharashtra's FDA has intervened in recent weeks on a series of unrelated but equally worrying matters: adulterated dairy products, contaminated medicines and unhealthy food around schools. Each represents an enforcement system reacting to long-standing issues with the food and medicines industries.

Testing had discovered that out of 308 samples collected, there were 79 substandard samples and 30 unsafe samples. The issue with the paneer was not merely the quality; in many cases, it seemed that manufacturers were allegedly substituting milk fat with cheaper vegetable oils and selling the resulting product as paneer.

Analogue paneer is not necessarily dangerous. The concern emerges when consumers are led to believe that a product is paneer when, in fact, its ingredients and nutritional profiles are fundamentally different to paneer. The crackdown on paneer raises a much larger issue on food labelling and transparency: how much does the average consumer know about the food they eat?

The FDA's action against Mumbai Parsi Dairy Farm also became part of the larger debate, although on a separate issue. The dairy's licence was suspended for hygiene issues, rather than contamination. Combining the two cases under the label of "unsafe dairy" would obscure an important difference. While one involved allegations of adulteration and misleading composition, the other was about food safety and hygiene.

If the dairy crackdown exposed issues of adulteration and standards, the pharmaceutical action exposed something far more serious. The Maharashtra FDA banned two cough syrups, Respifresh TR and Relife Syrup, after finding that they contained toxic diethylene glycol.

Diethylene glycol has been linked to cases of severe poisoning and deaths, including child deaths associated with contaminated cough syrups. Its reappearance in another set of medicines is therefore particularly alarming since it indicates that the problem cannot be treated as a one-time manufacturing accident. India is one of the world's largest producers of generic medicines and a major supplier of drugs internationally. Its pharmaceutical industry relies on public confidence in manufacturing standards and regulatory oversight.

Each new contamination case raises the same question: if toxic chemicals have already been identified as a known risk, why are they still making their way into finished medicines?

The issue is not merely whether regulators can detect contaminated products after they enter the market. The more important question is whether manufacturing and testing systems are strong enough to prevent such products from being produced and distributed in the first place.

The FDA's recent action has not focused solely on products found to be unsafe. The authority has also imposed restrictions on the availability of foods high in fat, salt and sugar near schools. The move is part of a wider attempt to address children's food environments before health problems develop.

Children surrounded by cheap, heavily processed foods may develop unhealthy eating habits long before the consequences manifest themselves. The restrictions represent a different model of regulation: prevention rather than seizure. The concurrent push for clearer nutrition labelling also reflects the same shift. Consumers, particularly parents and children, cannot make informed choices if packaging hides excessive levels of sugar, salt or fat behind technical ingredient lists and marketing language.

Probably, the value of the seized goods, amounting to ₹75 lakh, will provide the most significant takeaway from this incident for most people. It serves as an easily understandable metric and provides closure for those who want concrete action against adulteration. However, the actual value of the seizures is less than what they represent. The sum does not include the substandard drugs that were uncovered, the untested products in the market, or the manufacturers who continued their activities unaware of the law. In this sense, it is more important to focus on causes and consequences rather than the direct economic impact of the actions taken.

It is notable that the incidents leading to the raids represent different scenarios and seemingly have little in common. However, there is one significant connection – in all cases, the problem became apparent after the fact that it was already present. In other words, the Food Safety Authority, police, or drug controllers only got involved because the suspicious products were already on the shelves available for purchase.

Enforcement can remove unsafe products from the market. Prevention requires stronger systems that stop them from entering the market in the first place.

Maharashtra's FDA has undoubtedly had an unusually active few weeks. But describing the developments as a crackdown runs the risk of oversimplifying the matter.

The analogue paneer ban addresses adulteration and misleading food composition. The suspension of a dairy licence addresses hygiene standards. The cough syrup bans address potentially lethal pharmaceutical contamination. Restrictions near schools address the long-term public health consequences of unhealthy diets.

The real test of the FDA's recent actions will not be how much product is seized or how many licences are suspended. It will be whether the same violations continue to reappear months later. A ban can remove a contaminated cough syrup. A raid can seize adulterated paneer. A licence suspension can punish a business for hygiene failures. But if toxic chemicals continue entering medicines, if consumers cannot tell genuine dairy products from substitutes and if unhealthy food remains easier for children to access than nutritious alternatives, enforcement will remain a cycle of discovering problems after they have already occurred.

That is what ₹75 lakh in seized violations really represents. Not simply the value of products taken off the market, but the scale of a larger question: how much unsafe, adulterated or poorly regulated food and medicine has to be found before the systems responsible for preventing it are fixed?

References

. . .